Chiron Testifies to House Committee on Government Reform; President and CEO Howard Pien to Appear at Hearing Today.EMERYVILLE, Calif. -- Chiron Corporation Chiron Corporation was a multinational biotechnology firm based in Emeryville, California that was acquired by Novartis International AG on April 20 2006. It had offices and facilities in eighteen countries on five continents. (Nasdaq:CHIR CHIR Chiricahua National Monument (US National Park Service) ) announced that president and chief executive officer Howard Pien will appear before the U.S. House of Representatives Committee on Government Reform in Washington, D.C., today in a hearing titled, "The Nation's Flu Shot Shortage: Where Are We Today and How Prepared Are We for Tomorrow?" To learn more about the hearing, please visit http://reform.house.gov/. Other witnesses testifying at the hearing include representatives from the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), agency of the U.S. Public Health Service since 1973, with headquarters in Atlanta; it was established in 1946 as the Communicable Disease Center. , and the National Institute of Allergy and Infectious Diseases infectious diseases: see communicable diseases. , among others. As the hearing commences at 1:00 p.m. EST, Chiron will post its written testimony at www.chiron.com. A live webcast of the hearing will be available at http://reform.house.gov/GovReform/AboutUs/multimedia.htm. About Chiron Chiron delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology. The company works to deliver on the limitless promise of science and make a positive difference in people's lives. For more information about Chiron, please visit www.chiron.com. This news release contains forward-looking statements, including statements regarding remediation activities at Chiron's manufacturing facilities and supply of FLUVIRIN(R) influenza virus vaccine influenza virus vaccine n. A vaccine containing influenza virus, usually several strains of the virus, prepared in chick embryos and used to immunize against influenza. in future influenza seasons, that involve risks and uncertainties and are subject to change. No assurances can be given that additional issues with respect to FLUVIRIN or Chiron's manufacturing generally will not arise in the future or that regulatory authorities will not take adverse actions. Many factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including, among others, additional adverse developments resulting from Chiron's announcement of the suspension of its UK license to manufacture FLUVIRIN, including litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and investigations relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc such announcement. A discussion of the company's operations and financial condition, including factors that may affect its business and future prospects, is contained in documents the company has filed with the SEC, including the form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2003, and the form 10-Q Form 10-Q See 10-Q. for the quarter ended September 30, 2004, and will be contained in all subsequent periodic filings made with the SEC. These documents identify important factors that could cause the company's actual performance to differ from current expectations, including the outcome of clinical trials, regulatory approvals, manufacturing capabilities, litigation, and stock-price volatility. In particular, there can be no assurance that Chiron will complete remediation activities or resume sale of FLUVIRIN for the 2005-2006 influenza season or ever. In addition, the company may face additional competition in the influenza market in the future and challenges in distribution arrangements as a result of the recent FLUVIRIN announcements. We do not undertake an obligation to update the forward-looking information we are giving today. NOTE: FLUVIRIN is a trademark of Chiron Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion